[go: up one dir, main page]

LT3060577T - Rekombinantinio lubricino gamyba - Google Patents

Rekombinantinio lubricino gamyba

Info

Publication number
LT3060577T
LT3060577T LTEPPCT/US2014/061827T LT14061827T LT3060577T LT 3060577 T LT3060577 T LT 3060577T LT 14061827 T LT14061827 T LT 14061827T LT 3060577 T LT3060577 T LT 3060577T
Authority
LT
Lithuania
Prior art keywords
lubricine
recombinant
production
recombinant lubricine
Prior art date
Application number
LTEPPCT/US2014/061827T
Other languages
English (en)
Inventor
Tannin Schmidt
Gregory D. Jay
Original Assignee
Lubris Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lubris Llc filed Critical Lubris Llc
Publication of LT3060577T publication Critical patent/LT3060577T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725Proteoglycans, e.g. aggreccan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2014/061827T 2013-10-22 2014-10-22 Rekombinantinio lubricino gamyba LT3060577T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894366P 2013-10-22 2013-10-22
PCT/US2014/061827 WO2015061488A1 (en) 2013-10-22 2014-10-22 Production of recombinant lubricin

Publications (1)

Publication Number Publication Date
LT3060577T true LT3060577T (lt) 2021-12-27

Family

ID=52993344

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2014/061827T LT3060577T (lt) 2013-10-22 2014-10-22 Rekombinantinio lubricino gamyba

Country Status (22)

Country Link
US (5) US9982027B2 (lt)
EP (2) EP3060577B1 (lt)
JP (2) JP6669649B2 (lt)
KR (1) KR102488928B1 (lt)
CN (1) CN105899527A (lt)
AU (2) AU2014340080B2 (lt)
BR (1) BR112016008923A2 (lt)
CA (1) CA2927949A1 (lt)
CY (1) CY1124861T1 (lt)
DK (1) DK3060577T3 (lt)
ES (1) ES2891331T3 (lt)
HR (1) HRP20211497T1 (lt)
HU (1) HUE056397T2 (lt)
IL (2) IL245236B (lt)
LT (1) LT3060577T (lt)
MX (2) MX380735B (lt)
PL (1) PL3060577T3 (lt)
PT (1) PT3060577T (lt)
RU (1) RU2758115C2 (lt)
SG (2) SG10201913598TA (lt)
SI (1) SI3060577T1 (lt)
WO (2) WO2015060935A1 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110817C (en) 2009-05-22 2023-08-15 Lubris, Llc Application and uses of prg4 and therapeutic modulation thereof
PL2948553T3 (pl) * 2013-01-25 2020-11-16 Baylor College Of Medicine Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja) 2013-11-26 2019-09-04 ルブリス,エルエルシー. 細胞間相互作用を阻害するための組成物及び方法
MA53108A (fr) 2015-01-26 2021-05-12 Lubris Llc Utilisation de prg4 comme agent anti-inflammatoire
DK3300482T3 (da) 2015-05-19 2021-10-18 Lubris Llc Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer
EP3563894B1 (en) 2018-05-04 2021-12-22 Boehringer Ingelheim International GmbH Nebulizer and container
CN109055426B (zh) * 2018-08-06 2021-06-25 智享生物(苏州)有限公司 一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法
US20220127319A1 (en) 2019-01-15 2022-04-28 Cornell University Recombinant mucins, and compositions and methods for using the same
WO2020247440A1 (en) * 2019-06-03 2020-12-10 Lubris Llc Use of prg4 to treat cancer
JP2023515504A (ja) 2020-02-24 2023-04-13 ノバルティス アーゲー 組み換え産生されたポリペプチドの精製
US20250282981A1 (en) 2022-04-27 2025-09-11 Lubris Llc Methods of making polymer films
CN115177790A (zh) * 2022-06-27 2022-10-14 天津大学 透明质酸和润滑素蛋白协同修饰胶原蛋白基质的制备方法
CN115154667A (zh) * 2022-06-27 2022-10-11 天津大学 一种基于重组润滑素蛋白修饰的胶原蛋白基质的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2243827B2 (en) * 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US6530956B1 (en) * 1998-09-10 2003-03-11 Kevin A. Mansmann Resorbable scaffolds to promote cartilage regeneration
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
ATE437233T1 (de) 2001-01-26 2009-08-15 Selexis Sa Matrix-anheftungsregionen und verfahren zu deren verwendung
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
US7415381B2 (en) 2003-01-09 2008-08-19 Rhode Island Hospital, A Lifespan Partner Joint friction sensing
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
KR101078202B1 (ko) * 2003-08-14 2011-11-01 와이어쓰 엘엘씨 재조합 루브리신 분자 및 이의 용도
IN2014DN02484A (lt) 2003-10-24 2015-05-15 Selexis Sa
US20090155200A1 (en) 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
JP2008507553A (ja) 2004-07-23 2008-03-13 ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー 粘性補給のための組成物および方法
EP1827478A4 (en) 2004-12-03 2009-08-05 Mucosal Therapeutics Llc METHODS OF TREATING JOINED OR SICK JOINTS
US20070111327A1 (en) 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
SG176501A1 (en) * 2006-08-23 2011-12-29 Selexis Sa Matrix attachment regions (mars) for increasing transcription and uses thereof
CN101541308B (zh) 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
WO2008143816A1 (en) 2007-05-15 2008-11-27 Mucosal Therapeutics Compositions and methods for reducing friction between the surface of tendons or other soft tissues
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
SI2915529T1 (sl) 2008-05-07 2017-09-29 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
CN102438645A (zh) 2009-01-13 2012-05-02 卢布里斯有限责任公司 阴道上皮界面润滑的治疗调节
CA3110817C (en) 2009-05-22 2023-08-15 Lubris, Llc Application and uses of prg4 and therapeutic modulation thereof
CA2771110C (en) 2009-08-13 2019-02-26 Singularis, Inc. Prg4 treatment for interstitial cystitis
JP2013505013A (ja) 2009-09-18 2013-02-14 セレクシス エス.エー. 強化導入遺伝子発現およびプロセッシングの産物および方法
WO2011091000A2 (en) 2010-01-19 2011-07-28 Singularis, Inc. Oral care compositions and methods
US20130116186A1 (en) 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
US9982027B2 (en) 2013-10-22 2018-05-29 Lubris Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
JP6571101B2 (ja) 2013-11-26 2019-09-04 ルブリス,エルエルシー. 細胞間相互作用を阻害するための組成物及び方法
US20180161393A1 (en) 2015-01-26 2018-06-14 Lubris Llc Prg4 for treating gout and its symptoms
MA53108A (fr) 2015-01-26 2021-05-12 Lubris Llc Utilisation de prg4 comme agent anti-inflammatoire
DK3300482T3 (da) 2015-05-19 2021-10-18 Lubris Llc Brug af prg4 til at forbedre dynamisk synsstyrke og højere ordens aberrationer
US20170312335A1 (en) 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation

Also Published As

Publication number Publication date
EP3060577A4 (en) 2017-05-17
JP6669649B2 (ja) 2020-03-18
EP3060577B1 (en) 2021-07-07
JP2020039348A (ja) 2020-03-19
EP3971203A1 (en) 2022-03-23
AU2014340080B2 (en) 2018-12-06
HRP20211497T1 (hr) 2021-12-24
CY1124861T1 (el) 2022-11-25
US9982027B2 (en) 2018-05-29
BR112016008923A2 (pt) 2017-09-19
JP6970164B2 (ja) 2021-11-24
EP3060577A1 (en) 2016-08-31
AU2014340080A1 (en) 2016-06-02
KR20160086843A (ko) 2016-07-20
MX380735B (es) 2025-03-12
US20160304572A1 (en) 2016-10-20
SI3060577T1 (sl) 2021-12-31
DK3060577T3 (da) 2021-10-04
PT3060577T (pt) 2021-10-01
RU2016119532A3 (lt) 2018-05-16
SG11201603151VA (en) 2016-05-30
US20210130427A1 (en) 2021-05-06
US11485764B2 (en) 2022-11-01
US20190270783A1 (en) 2019-09-05
US20230234999A1 (en) 2023-07-27
MX2021003243A (es) 2021-05-12
KR102488928B1 (ko) 2023-01-13
CN105899527A (zh) 2016-08-24
US10723773B2 (en) 2020-07-28
RU2016119532A (ru) 2017-11-28
JP2016535590A (ja) 2016-11-17
US12435115B2 (en) 2025-10-07
CA2927949A1 (en) 2015-04-30
AU2019201478B2 (en) 2021-07-08
ES2891331T3 (es) 2022-01-27
IL245236B (en) 2021-12-01
AU2019201478A1 (en) 2019-03-28
IL245236A0 (en) 2016-06-30
HUE056397T2 (hu) 2022-02-28
PL3060577T3 (pl) 2022-01-24
US10125180B2 (en) 2018-11-13
RU2758115C2 (ru) 2021-10-26
WO2015061488A1 (en) 2015-04-30
US20160250286A1 (en) 2016-09-01
MX2016005302A (es) 2017-02-15
SG10201913598TA (en) 2020-02-27
WO2015060935A1 (en) 2015-04-30
IL283447A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
IL269227B (en) Solid forms of treprostinil
LT3060577T (lt) Rekombinantinio lubricino gamyba
EP2982689A4 (en) FC-REGIONS-VARIATIONS
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
HRP20180684T1 (hr) Kombinacija lijekova
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
DK2970954T3 (da) Modifikation af polypeptider
PT2953948T (pt) Antagonistas de integrina fluorada
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
HUE037417T2 (hu) Szubsztituált imidazopiridazinok
DK2943561T3 (da) Fotobioreaktor
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T3 (da) Bindestrimler
EP2945942A4 (en) Voriconazole IMMUNOASSAY
DK2946640T3 (da) Langmuir-probe
IL240698B (en) Producing a fragment/reactive material assembly
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2988738A4 (en) THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
DK3071227T3 (da) Fiskevaccine
IL239971A0 (en) Isometheptene isomer
HRP20190218T1 (hr) Produkcija glikoproteina s povećanom popunjenosti mjesta n-glikolizacije